Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: a genomic and phenotypic study
The Lancet Microbe · 2025-08 · 6 (8) · 101114
DOI: 10.1016/j.lanmic.2025.101114 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Microbe, 2025-08. Verfasst von Yinggai Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Department of Medical Microbiology and Radboudumc-CWZ Cen…. Hauptthemen laut MEDLINE: Aspergillus fumigatus, Triazoles, Drug Resistance, Fungal, Antifungal Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Aspergillus fumigatus is the main cause of invasive aspergillosis and triazole antifungals are the primary treatment option. The effectiveness of triazole therapy is hampered by the emergence of resistance, mainly caused by mutations in the cyp51A gene and a tandem repeat (TR) of 34 bases (TR34/Leu98His) and 46 bases (TR46/Tyr121Phe/Thr289Ala) in the promoter region, which correspond with signature triazole resistance phenotypes. We aimed to investigate the occurrence of triazole phenotype and genotype variation over a 29-year period in the Netherlands. METHODS: In this genomic and phenotypic study, we screened all clinical A fumigatus isolates from Dutch hospitals collected between Jan 6, 1994, and Dec 31, 2022, for resistance to triazole using agar-based methods, and characterised them by sequencing the cyp51A gene and in vitro susceptibility testing using the European Committee on Antimicrobial Susceptibility Testing reference method. Whole-genome sequencing was performed on selected isolates, including those harboring TR34 variants, high-frequency single-nucleotide polymorphisms, and wild-type strains. Clinical information such as age, underlying disease, diagnosis, therapy, and outcomes was collected for patients who had isolates cultured at the Radboud University Medical Centre, Nijmegen, Netherlands, between Jan 1, 2017, and Dec 31, 2022. FINDINGS: 1979 (15·6%) of the screened 12 679 A fumigatus isolates harboured cyp51A triazole resistance mutations, predominately TR34/Leu98His sensu stricto in 1338 (67·6%) resistant isolates and TR46/Tyr121Phe/Thr289Ala sensu stricto in 332 (16·8%) resistant isolates. Phenotype and genotype variations were observed in 325 (17·2%) triazole resistant isolates harbouring a TR-resistance mechanism, including 12 cyp51A genotype variants. Whole-genome sequencing showed that isolates with combinations of TR34-based and TR46-based polymorphisms seemed to be derived from separate populations, but there was some overlap. 59 cases of proven or probable invasive aspergillosis were identified, including 13 triazole-resistant cases, of which three were caused by genotype variants. Mixed genotype infection was observed in 11 (84·6%) of 13 triazole-resistant patients and the number of antifungal treatment switches was higher compared with triazole-susceptible disease (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Department of Medical Microbiology and Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijm…
- Department of Medical Microbiology and Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, Netherlands.
- Center for Infectious Disease Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
- Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China; Research Center for Medical Mycology, Peking Un…
- Department of Medical Microbiology and Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, Netherlands; Center for Infectious Disease Research, Diagnostics and Laboratory Survei…
Förderung
- Wellcome Trust
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Song, Y., Buil, J. B., Rhodes, J., Zoll, J., Tehupeiory-Kooreman, M., Ergün, M., Zhang, J., Li, R., Bosch, T., Melchers, W. J. G., & Verweij, P. E. (2025). Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: a genomic and phenotypic study. The Lancet Microbe, 6(8), 101114. https://doi.org/10.1016/j.lanmic.2025.101114
Vancouver
Song Y, Buil JB, Rhodes J, Zoll J, Tehupeiory-Kooreman M, Ergün M, et al. Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: a genomic and phenotypic study. The Lancet Microbe. 2025;6(8):101114. doi:10.1016/j.lanmic.2025.101114
BibTeX
@article{Song2025,
author = {Song, Yinggai and Buil, Jochem B and Rhodes, Johanna and Zoll, Jan and Tehupeiory-Kooreman, Marlou and Ergün, Mehmet and Zhang, Jianhua and Li, Ruoyu and Bosch, Thijs and Melchers, Willem J G and Verweij, Paul E},
title = {Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: a genomic and phenotypic study},
journal = {The Lancet Microbe},
year = {2025},
volume = {6},
number = {8},
pages = {101114},
doi = {10.1016/j.lanmic.2025.101114}
}
EUVIMED